{"entity":{"id":"rayzebio","kind":"company","name":"RayzeBio (BMS)","aka":[],"tldr":"RayzeBio is the actinium-225 radiopharma company that BMS bought for $4.1B; its RYZ101 is in phase 3.","summary":"RayzeBio, based in San Diego, is the actinium-225 radiopharmaceutical company that Bristol Myers Squibb bought for 4.1 billion dollars, and its RYZ101 is in phase 3. RYZ101 is actinium-225 DOTATATE for somatostatin-receptor-positive neuroendocrine tumours, RYZ801 is an actinium-225 PSMA agent, and the company built in-house actinium-225 manufacturing. OnCo links it to neuroendocrine tumours, to peptide receptor radionuclide therapy and targeted alpha therapy, to the actinium-225 DOTATATE drug record, and to the radiopharmaceutical roadmap from iodine through lutetium to actinium. Whether an alpha emitter can improve on lutetium-based radioligand therapy is the question RYZ101's phase 3 will answer. Actinium-225 DOTATATE has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.rayzebio.com"}],"tags":[],"related":[],"cancers":[],"sections":["radiopharma"],"technologies":[],"targets":[],"drugs":["ryz101"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06590857","nct06726161"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Diego, CA","country":"US","companyType":"radiopharma","website":"https://www.rayzebio.com","investors":[],"funding":[]},"route":"/companies/rayzebio/","neighbours":{"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"drug":[{"id":"ryz101","kind":"drug","name":"Actinium-225 DOTATATE","route":"/drugs/ryz101/"}],"trial":[{"id":"nct06726161","kind":"trial","name":"Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC","route":"/trials/nct06726161/"},{"id":"nct06590857","kind":"trial","name":"Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.","route":"/trials/nct06590857/"}],"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}],"technology":[{"id":"actinium-225-supply","kind":"technology","name":"Actinium-225 supply: thorium stocks, accelerators and radium targets","route":"/technologies/actinium-225-supply/"},{"id":"prrt","kind":"technology","name":"Peptide receptor radionuclide therapy (PRRT)","route":"/technologies/prrt/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"roadmap":[{"id":"radiopharma-roadmap","kind":"roadmap","name":"Radiopharmaceutical roadmap: iodine → lutetium → actinium","route":"/roadmaps/radiopharma-roadmap/"}]}}